Amgen has announced promising results from a late-stage trial involving a combination of its drug Imdelltra and AstraZeneca's immunotherapy Imfinzi. The study, released on Saturday, found that adding Imdelltra to Imfinzi reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer. This form of lung cancer is particularly aggressive and has spread beyond the lung where it originated.
The findings suggest that the drug combo could significantly extend the lifespan of patients battling this fast-growing disease. Amgen's Imdelltra, when used alongside AstraZeneca's Imfinzi, demonstrated a substantial improvement in survival rates, offering new hope for those diagnosed with extensive-stage small cell lung cancer.
The results were published on Saturday, October 24, 2026, marking a potential breakthrough in the treatment of this notoriously difficult-to-treat cancer. The study highlights the potential of combining different immunotherapies to enhance patient outcomes.